Skip to content
value.today

ReAlta Life Sciences, Inc.

🇺🇸 Norfolk, Virginia, USAPharmaceuticalsFounded 2017

Formerly ReAlta Life Sciences, LLC

Total raised
$94 M
5 rounds on record
Latest round
$25 M
Dec 2024
First round on record
Sep 2018
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ReAlta Life Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$25 MNo. 5$10 to $50 million

ReAlta Life Sciences, Inc.: Raise no. 5, Dec 2024

Investors in this round

109 investors had bought by the notice of May 21, 2025: 109 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Shares of Series A-6 Preferred Stock and underlying shares of common stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Marek · Executive Officer, Director
  • John Rickman · Executive Officer
  • Kenji Cunnion · Executive Officer
  • Neel Krishna · Executive Officer
  • Paolo Martini · Executive Officer
  • Andrew Miller · Director
  • Christi Shaw · Director
  • Edward Heidt, Jr. · Director
  • Emma Reeve · Director
  • Frank Gadams · Director
  • Laurie Glimcher · Director
  • Lewis Williams · Director
  • Mert Aktar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Rickman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 21, 2025. Read the notice at the SEC.

equitySEC
Nov 2023$30 MNo. 4$10 to $50 million

ReAlta Life Sciences, Inc.: Raise no. 4, Nov 2023

Investors in this round

149 investors had bought by the notice of May 21, 2025: 149 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Shares of Series A-5 Preferred Stock and underlying shares of common stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Marek · Executive Officer, Director
  • John Rickman · Executive Officer
  • Kenji Cunnion · Executive Officer
  • Neel Krishna · Executive Officer
  • Paolo Martini · Executive Officer
  • Andrew Miller · Director
  • Christi Shaw · Director
  • Edward Heidt, Jr. · Director
  • Emma Reeve · Director
  • Frank Gadams · Director
  • Laurie Glimcher · Director
  • Lewis Williams · Director
  • Mert Aktar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Rickman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 21, 2025. Read the notice at the SEC.

equitySEC
Feb 2023$12 MNo. 3$10 to $50 million

ReAlta Life Sciences, Inc.: Raise no. 3, Feb 2023

Investors in this round

85 investors had bought by the notice of May 21, 2025: 85 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Shares of Series A-4 Preferred Stock and underlying shares of common stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Marek · Executive Officer, Director
  • John Rickman · Executive Officer
  • Kenji Cunnion · Executive Officer
  • Neel Krishna · Executive Officer
  • Paolo Martini · Executive Officer
  • Andrew Miller · Director
  • Christi Shaw · Director
  • Edward Heidt, Jr. · Director
  • Emma Reeve · Director
  • Frank Gadams · Director
  • Laurie Glimcher · Director
  • Lewis Williams · Director
  • Mert Aktar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Rickman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 21, 2025. Read the notice at the SEC.

equitySEC
Dec 2020$23 MNo. 2$10 to $50 million

ReAlta Life Sciences, Inc.: Raise no. 2, Dec 2020

Investors in this round

92 investors had bought by the notice of Sep 13, 2023: 92 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Shares of Series A-3 Preferred Stock and underlying shares of common stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Rickman · Executive Officer
  • Kathryn Abshire · Executive Officer
  • Kenji Cunnion · Executive Officer, Director
  • Neel Krishna · Executive Officer
  • Ulrich Thienel · Executive Officer, Director
  • Azmi Nabulsi · Director
  • Barry Strasnick · Director
  • Christine Neikirk · Director
  • Deborah Geraghty · Director
  • Edward Heidt, Jr. · Director
  • Frank Gadams · Director
  • Jonathan Zalevsky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ulrich Thienel, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 13, 2023. Read the notice at the SEC.

equitySEC
Sep 2018$5 MNo. 1$2 to $10 million

ReAlta Life Sciences, Inc.: Raise no. 1, Sep 2018

Investors in this round

1 investor had bought by the notice of Sep 12, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $12 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$14,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenji Kerry Cunnion · Executive Officer, Director · Director and Chief Medical Officer
  • Neel Kerry Krishna · Executive Officer · Chief Science Officer
  • Thomas Kerry McCarter · Executive Officer · Managing Director
  • Edward Kerry Heidt, Jr. · Director
  • Jerry Kerry Nadler · Director
  • John Kerry Harding · Director
  • Ulrich Kerry Thienel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Kerry McCarter, Managing Director. Source: SEC Form D, newest notice filed Sep 12, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ReAlta Life Sciences, Inc. chose not to state its revenue in its newest notice of a funding round (May 2025).

    SEC Form D · May 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2025

That is all the official record says: ReAlta Life Sciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of ReAlta Life Sciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 149 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ReAlta Life Sciences, Inc.
NameRoleNamed in
David MarekExecutive officerMay 2025
John RickmanExecutive officerMay 2025
Kenji CunnionExecutive officerMay 2025
Neel KrishnaExecutive officerMay 2025
Paolo MartiniExecutive officerMay 2025
Kathryn AbshireExecutive officerSep 2023
Ulrich ThienelExecutive officerSep 2023
Kenji Kerry CunnionDirector and Chief Medical OfficerSep 2018
Neel Kerry KrishnaChief Science OfficerSep 2018
Thomas Kerry McCarterManaging DirectorSep 2018
Andrew MillerDirectorMay 2025
Christi ShawDirectorMay 2025
David MarekDirectorMay 2025
Edward Heidt, Jr.DirectorMay 2025
Emma ReeveDirectorMay 2025
Frank GadamsDirectorMay 2025
Laurie GlimcherDirectorMay 2025
Lewis WilliamsDirectorMay 2025
Mert AktarDirectorMay 2025
Azmi NabulsiDirectorSep 2023
Barry StrasnickDirectorSep 2023
Christine NeikirkDirectorSep 2023
Deborah GeraghtyDirectorSep 2023
Jonathan ZalevskyDirectorSep 2023
Kenji CunnionDirectorSep 2023
Ulrich ThienelDirectorSep 2023
Edward Kerry Heidt, Jr.DirectorSep 2018
Jerry Kerry NadlerDirectorSep 2018
John Kerry HardingDirectorSep 2018
Kenji Kerry CunnionDirector and Chief Medical OfficerSep 2018
Ulrich Kerry ThienelDirectorSep 2018